Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Equinix | Eli Lilly and Company | Apple | |
|---|---|---|---|
| Moat rating | wide The FY2025 10-K (filed 2026-02-11) grounds the advantage in an asset that took 27 years to assemble and that a competitor cannot buy: "Over our 27-year history, we have curated a diverse, industry-leading ecosystem of more than 500,000 interconnections", "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", across "280 data centers, in 77 markets in 36 countries", with "99.9999%+ operational uptime" delivered in 2025 and no single customer at 10% of revenue. Because the value of each IBX rises with who else is already inside it, incumbency compounds rather than decays. The counterweight is real and disclosed: Item 1A says "The global multi-tenant data center market is highly fragmented. It is estimated that we are one of more than 2,400 companies that provide these offerings around the world", and warns that competitors "may adopt aggressive pricing policies". That caps the pricing that the moat converts into, not its durability — the fragmentation sits in commodity space-and-power, while the interconnection density the filing describes has no comparable substitute. FY2025 revenue of $9.217B with operating margin recovering to 20.0% from 15.2% in FY2024 is consistent with the incumbency holding. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Argued, not assumed. The FY2025 10-K does evidence a real moat in margin: total gross margin percentage rose 44.1% (2023) to 46.2% (2024) to 46.9% (2025) in markets the same filing describes as characterised by 'aggressive price competition, downward pressure on gross margins.' But the filing bounds the claim itself: it concedes 'a minority market share in the global smartphone, personal computer, tablet and wearables markets,' it discloses no retention, active-device or installed-base figure anywhere (its only 'large installed bases of active devices' reference describes competitors), and it discloses that both of the highest-margin layers are already being cut down by force -- Apple is 'currently subject to a court order preventing it from imposing any commission or fee on certain purchases' on the U.S. App Store storefront, has had to open 'alternative methods of distribution for iOS and iPadOS apps, alternative payment processing' in the EU, and warns that a reversal on appeal in the Google search case could impose remedies 'prohibiting Google from offering the Company commercial terms for search distribution.' A moat that earns 46.9% gross margin but whose most profitable layer is being narrowed by two courts and a regulator is narrow, not wide. |
| Moat type | network effects The 10-K names the mechanism itself, twice and unprompted: "As more customers choose Equinix for high connectivity and performance reliability at the metro edge, it benefits their suppliers and business partners to colocate in the same data centers and connect directly with each other. This adjacency creates a network effect that attracts new customers while continuously enhancing our value proposition to existing customers", and in the Competitive Landscape section, "This ecosystem creates a network effect that improves performance and lowers the cost for our customers". The evidence is the count of participants rather than any patent or unit-cost claim — 500,000+ interconnections, 2,000+ network service providers, a leading share of cloud on-ramps, an Internet Exchange the filing calls "the largest global peering solution". Switching costs are a genuine second layer (fixed-duration contracts billed on space and power, physical cross connects into resident counterparties), but they are what holds a customer already inside the ecosystem; the reason to enter in the first place is who is already there. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | switching costs The 10-K locates the durable advantage in an integrated stack and its third-party ecosystem, not in patents: it names 'a strong third-party software and accessories ecosystem' among the principal competitive factors and states the Company 'designs and develops nearly the entire solution for its products, including the hardware, operating system, numerous software applications and related services,' while explicitly disclaiming IP as the source -- 'No single intellectual property right is solely responsible for protecting the Company's products and services' and the Company 'relies primarily on the innovative skills, technical competence and marketing abilities of its personnel.' The remedies now in force confirm the diagnosis negatively: the same filing describes being required to permit alternative distribution and alternative payment processing in the EU and being barred from charging commission on certain linked-out purchases in the U.S. -- remedies aimed squarely at lowering the cost of leaving Apple's rails, which is what a switching-cost moat is. |
| Leadership | clear leader Leadership is claimed on interconnection, not on square footage, and the filing's own evidence is about density: "our position is unmatched in the industry" is supported by 2,000+ resident network service providers, "a leading market share of cloud-on ramps", 500,000+ interconnections and an Internet Exchange described as "the largest global peering solution", across 36 countries. The band is read against neutral, ecosystem-dense colocation, where that footprint has no direct analogue. It is deliberately not read against total data centre capacity: the same 10-K puts Equinix among "more than 2,400 companies" in a "highly fragmented" MTDC market, and Item 1A concedes the company must compete for land and power against "new market entrants" drawn in by AI. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | fast follower Apple leads on integration and margin rather than on units, and the filing says so: it 'has a minority market share in the global smartphone, personal computer, tablet and wearables markets,' while competitors have 'broad product lines, low-priced products, large installed bases of active devices, and large customer bases.' On the AI axis that defines this graph, Apple is following rather than leading -- it now licenses a rival's frontier models to power Siri (see the Apple Intelligence / Siri row and its citation) while pushing its own advantage down into silicon. |
| Pricing power | moderate Contract structure supports price: fixed-duration agreements billed on space and power plus per-connection interconnection fees, an installed base too physically entangled to move cheaply, and 99.9999%+ uptime in 2025 as the thing being paid for. FY2025 revenue of $9.217B grew about 5% on FY2024's $8.748B while operating margin recovered to 20.0% from 15.2%, so pricing and cost were at least held. But the filing itself refuses the strong band: competitors "may adopt aggressive pricing policies, especially if they are not highly leveraged or have lower return thresholds than we do. As a result, we may suffer from pricing pressure that would adversely affect our ability to generate revenues", and some rivals bundle communications or cloud services against bare colocation. Power procurement is a further pass-through risk the filing flags. Price is defended, not dictated. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | strong The 10-K's own gross-margin table: total gross margin percentage 44.1% (2023) to 46.2% (2024) to 46.9% (2025), with Services at 75.4% versus Products at 36.8%, and iPhone net sales rising 'due to higher net sales of Pro models' -- mix moving up, not down. Held against the filing's own hedge that 'gross margins will be subject to volatility and downward pressure,' the realised trend is the stronger evidence. |
| Summary | Equinix is a network-neutral, multi-tenant colocation and interconnection REIT: it does not sell compute, it sells the metro-edge real estate where networks, clouds and enterprises physically meet. The FY2025 10-K describes the platform as "280 data centers, in 77 markets in 36 countries" serving "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", carrying "more than 500,000 interconnections" curated over 27 years, with 61% of 2025 revenue recognised outside the U.S. Revenue is structurally recurring — infrastructure offerings are "billed based on the space and power a customer consumes" under fixed-duration contracts generating MRR, interconnection is "billed based on the outbound connections from a customer" — and no customer reached 10% of 2025 revenue. AI enters the story as demand rather than as a product: the filing positions Equinix as the interconnect point for "model providers, data platforms, neoclouds and gateways", and pushes core hyperscale capacity into xScale, which is "developed and operated through our joint venture partnership arrangements". The bear case is in the company's own Item 1A. The MTDC market is "highly fragmented", Equinix being "one of more than 2,400 companies"; competitors "may adopt aggressive pricing policies"; the AI build-out invites "significant investments in the data center industry by both current competitors and new investors", after which "we could lose market share" and must "compete against certain of these competitors to secure the land and power needed for our expansion plans". Product extension has also failed before — the filing notes past offerings "have been or are being discontinued, including the Equinix Metal product". The honest reading: the interconnection ecosystem is close to unreplicable and the moat sits there; the capacity business around it is a capital race Equinix enters with scale but no immunity. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Apple's moat is usually asserted through the ecosystem; the FY2025 10-K neither quantifies nor claims retention, so the evidence has to be read elsewhere in the filing. Where it does show is mix and margin: Services reached $109.2B of $416.2B net sales (+14%) at a 75.4% gross margin against 36.8% on Products, so 26% of revenue delivered $82.3B of the $195.2B total gross margin, and iPhone grew 'due to higher net sales of Pro models.' That profit concentration is also the vulnerability the filing itself flags: Apple 'earns revenue from licensing arrangements with Google LLC and other companies to offer their search services on the Company's platforms,' arrangements 'currently subject to government investigations and legal proceedings' after Google was found to have violated U.S. antitrust laws on August 5, 2024 and the D.C. District Court ordered remedies on September 2, 2025 -- with the 10-K warning that a reversal on appeal could impose DOJ's proposed remedies 'prohibiting Google from offering the Company commercial terms for search distribution,' which 'could materially adversely affect the Company's ability to earn revenue from such licensing arrangements.' Apple never discloses the size of that payment in the filing -- the concentration is admitted but not measured. Alongside it, the App Store toll has already been reduced in both jurisdictions. What is not in dispute is the vertical integration: Apple designs the silicon and now the cellular modem, and uses 'custom components available from only one source.' Read together: a genuine, margin-visible switching-cost moat around an integrated stack, with its two most profitable layers under active legal reduction. |
| Chain position | Equinix is the neutral meeting point of the AI and cloud supply chain rather than a link in its manufacturing path: it houses other companies' compute and sells the adjacency between them. The 10-K places it between the network layer (2,000+ service providers), the cloud layer ("a leading market share of cloud-on ramps") and enterprise consumers who "assemble these capabilities into operational stacks", and describes an AI ecosystem "of model providers, data platforms, neoclouds and gateways" curated for enterprise AI demand. Core hyperscale training capacity sits beside that, not inside it, in xScale, built with JV partners so hyperscalers "add to their core hyperscale data center deployments and existing customer access points at Equinix". The revenue is therefore levered to AI's distribution and inference edge more than to training-cluster buildout. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Applications-layer name in the AI chain: the 10-K describes designing 'nearly the entire solution' and using custom components 'available from only one source,' making Apple a large, concentrated buyer of leading-edge silicon rather than a supplier of AI compute to anyone else. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.11 at weight 0.20 · swarm bullish Editorial prior, not backtested. |